IL238443B - Activin-actrii antagonists and their use for the treatment of bone and other disorders - Google Patents

Activin-actrii antagonists and their use for the treatment of bone and other disorders

Info

Publication number
IL238443B
IL238443B IL238443A IL23844315A IL238443B IL 238443 B IL238443 B IL 238443B IL 238443 A IL238443 A IL 238443A IL 23844315 A IL23844315 A IL 23844315A IL 238443 B IL238443 B IL 238443B
Authority
IL
Israel
Prior art keywords
activin
disorders
treating bone
actrii antagonists
actrii
Prior art date
Application number
IL238443A
Other languages
English (en)
Hebrew (he)
Other versions
IL238443A0 (en
Original Assignee
Celgene Corp
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Univ Washington filed Critical Celgene Corp
Publication of IL238443A0 publication Critical patent/IL238443A0/en
Publication of IL238443B publication Critical patent/IL238443B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796Receptors; Cell surface antigens; Cell surface determinants for hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL238443A 2012-11-02 2015-04-22 Activin-actrii antagonists and their use for the treatment of bone and other disorders IL238443B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721898P 2012-11-02 2012-11-02
US201261740665P 2012-12-21 2012-12-21
PCT/US2013/068009 WO2014071158A1 (en) 2012-11-02 2013-11-01 Activin-actrii antagonists and uses for treating bone and other disorders

Publications (2)

Publication Number Publication Date
IL238443A0 IL238443A0 (en) 2015-06-30
IL238443B true IL238443B (en) 2019-07-31

Family

ID=50628091

Family Applications (2)

Application Number Title Priority Date Filing Date
IL238443A IL238443B (en) 2012-11-02 2015-04-22 Activin-actrii antagonists and their use for the treatment of bone and other disorders
IL267066A IL267066B (en) 2012-11-02 2019-06-03 Activin-actrii antagonists and their use for the treatment of bone and other disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL267066A IL267066B (en) 2012-11-02 2019-06-03 Activin-actrii antagonists and their use for the treatment of bone and other disorders

Country Status (15)

Country Link
US (3) US10195249B2 (enExample)
EP (3) EP2914277B1 (enExample)
JP (4) JP2016504275A (enExample)
KR (3) KR102279522B1 (enExample)
CN (1) CN104936605A (enExample)
AU (3) AU2013337677B2 (enExample)
BR (1) BR112015009948B1 (enExample)
CA (2) CA2890217C (enExample)
ES (2) ES2652437T3 (enExample)
IL (2) IL238443B (enExample)
MX (2) MX366336B (enExample)
NZ (1) NZ707477A (enExample)
RU (2) RU2678117C2 (enExample)
WO (1) WO2014071158A1 (enExample)
ZA (1) ZA201503135B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58231B1 (sr) 2005-11-23 2019-03-29 Acceleron Pharma Inc Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR101526613B1 (ko) 2007-02-01 2015-06-26 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TW201808334A (zh) 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE063136T2 (hu) 2008-08-14 2023-12-28 Acceleron Pharma Inc GDF-Csapdák
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
IL252631B2 (en) 2014-12-03 2024-06-01 Celgene Corp ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
MX2017013520A (es) 2015-04-22 2018-05-22 Alivegen Usa Inc Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
RS62011B1 (sr) * 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
WO2018067873A2 (en) * 2016-10-05 2018-04-12 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
CN116650622A (zh) * 2016-10-05 2023-08-29 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
DK3600415T3 (da) 2017-03-24 2025-12-01 Novartis Ag Antistof mod activin-receptor type ii-receptor til anvendelse ved behandling af hjertesvigt
CN107320718B (zh) * 2017-05-23 2020-12-11 余红 促生长激素释放激素激动剂在制备抗血管钙化药物中的应用
JP2021522795A (ja) 2018-05-03 2021-09-02 アクセルロン ファーマ インコーポレイテッド TGFβ−スーパーファミリーのリガンドの新規バインダーおよびその使用
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
US20240366722A1 (en) * 2021-08-16 2024-11-07 Acceleron Pharma Inc. Compositions and methods for treating renal diseases or conditions

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
WO1992004913A1 (en) 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ ソーク インスティテュート フォア バイオロジカル スタディーズ アクチビン/TGF―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ATE175441T1 (de) 1991-06-25 1999-01-15 Genetics Inst Bmp-9 zusammensetzungen
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP1475440A3 (en) 1993-01-12 2004-11-17 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
AU677849B2 (en) 1993-05-12 1997-05-08 Genetics Institute, Llc BMP-10 compositions
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
EP0771873A3 (en) 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
EP0939816A1 (en) 1996-10-25 1999-09-08 G.D. SEARLE & CO. Circularly permuted erythropoietin receptor agonists
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CA2297489A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
EP1015468A4 (en) 1997-08-29 2000-09-06 Human Genome Sciences Inc FOLLISTATINE-3
NZ503489A (en) 1997-10-03 2002-11-26 Chugai Pharmaceutical Co Ltd Natural humanized antibody, method of production and pharmaceutical composition
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
CA2343268A1 (en) 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
AU5502799A (en) 1998-09-22 2000-04-10 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2365449A1 (en) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibitor of the growth of androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
KR20020065517A (ko) 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
NZ519546A (en) 1999-12-15 2005-07-29 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
ATE291436T2 (de) 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
AU2001269709A1 (en) 2000-07-19 2002-02-05 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
AU2567002A (en) 2000-11-20 2002-05-27 Univ Illinois Membrane scaffold proteins
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
EP1369130A1 (en) 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
EP1416273B1 (en) 2001-07-17 2009-11-11 Teijin Limited Method of selecting substance characterized by assaying ppard activating effect and drug
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
EP1487472B1 (en) 2001-12-06 2019-06-26 Fibrogen, Inc. Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
AU2003216250A1 (en) 2002-02-11 2003-09-04 Genentech, Inc. Antibody variants with faster antigen association rates
AU2003216345A1 (en) 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
WO2003072715A2 (en) 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
KR20050083635A (ko) 2002-08-16 2005-08-26 와이어쓰 Bmp-2 에스트로겐 반응 요소 및 이의 사용 방법
CA2501936A1 (en) 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2004064770A2 (en) 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
NZ541593A (en) 2003-02-07 2009-05-31 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2010019832A2 (en) 2008-08-13 2010-02-18 Designer Molecules, Inc. Amide-extended crosslinking compounds and methods for use thereof
US20070184052A1 (en) 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7611465B2 (en) * 2003-07-15 2009-11-03 Board Of Regents, The University Of Texas System Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
DE10335211A1 (de) 2003-08-01 2005-02-17 Robert Bosch Gmbh Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
JP4987484B2 (ja) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 補体結合が低下した抗癌抗体
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
CA2561317A1 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
US7459527B2 (en) 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
EP1771557B1 (en) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8617815B2 (en) 2004-08-05 2013-12-31 The Regents Of The University Of California Molecules with effects on cellular development and function
WO2006020884A2 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
US8435948B2 (en) 2004-09-29 2013-05-07 Mount Sinai School Of Medicine Of New York University Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
US7879569B2 (en) 2004-11-09 2011-02-01 The Trustees Of The University Of Pennsylvania Methods for diagnosis of myelodysplastic syndromes (MDS)
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
CA2597925A1 (en) 2005-02-16 2006-08-24 The General Hospital Corporation Use of a human hemojuvelin product to regulate hepcidin-mediated iron metabolism
KR20080003929A (ko) 2005-04-26 2008-01-08 아지노모토 가부시키가이샤 골수 적혈구 전구 세포 분화 촉진제
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
PT1931697E (pt) 2005-09-28 2010-12-06 Zymogenetics Inc Antagonistas de il-17a e il-17f e processos para a sua utilização
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
RS58231B1 (sr) * 2005-11-23 2019-03-29 Acceleron Pharma Inc Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA2856436A1 (en) 2005-12-06 2007-06-14 Amgen Inc. Uses of myostatin antagonists
JP2009519984A (ja) 2005-12-20 2009-05-21 メルク フロスト カナダ リミテツド ステアロイル−補酵素δ−9デサチュラーゼ阻害剤としての芳香族複素環化合物
CA2634940A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
JP4925364B2 (ja) 2006-01-20 2012-04-25 ベックマン コールター, インコーポレイテッド 鉄欠乏を検出する方法
US7820721B2 (en) 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN101394738A (zh) 2006-02-28 2009-03-25 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
US8008074B2 (en) * 2006-03-20 2011-08-30 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
EP2007813A2 (en) 2006-04-14 2008-12-31 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
WO2007133653A2 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
NZ574331A (en) 2006-07-21 2011-01-28 Lyne Lab Liquid compositions of calcium acetate
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5468187B2 (ja) 2006-09-26 2014-04-09 ポリプラスチックス株式会社 ポリアセタール樹脂組成物
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
WO2008072723A1 (ja) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009006651A (es) 2006-12-18 2009-08-26 Acceleron Pharma Inc Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
KR101526613B1 (ko) 2007-02-01 2015-06-26 악셀레론 파마 인코포레이티드 액티빈-actrⅱa 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TW201808334A (zh) 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
WO2008151078A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
US20100279409A1 (en) 2007-09-13 2010-11-04 Neil Robson Method for modifying celluar immune resonse by modulating activin activity
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP5583591B2 (ja) 2007-11-21 2014-09-03 アムジエン・インコーポレーテツド Wise結合抗体及びエピトープ
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US8814094B2 (en) 2008-04-04 2014-08-26 Tactair Fluid Controls, Inc. Locking mechanism with bi-modal actuator
EP2283119B1 (en) 2008-05-06 2015-01-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
JP2011521969A (ja) 2008-05-30 2011-07-28 スムマ ヘルス システムズ エルエルシー 眼疾患を治療するためのTGF−β受容体阻害剤又はアクチビン様キナーゼ(ALK)5阻害剤、A−83−01及びSB−431542の使用方法及び創傷治療条件
WO2009158033A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP3415161A1 (en) 2008-06-26 2018-12-19 Acceleron Pharma Inc. The use of an actriib antagonist for the treatment of anemia
HUE063136T2 (hu) 2008-08-14 2023-12-28 Acceleron Pharma Inc GDF-Csapdák
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
EA201100832A1 (ru) 2008-11-26 2011-12-30 Амген Инк. Варианты полипептидов рецептора iib активина и их применение
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
CN102307598A (zh) * 2009-02-05 2012-01-04 迪格纳生物技术公司 TGF-β1抑制肽的药物制剂
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
JP2012524073A (ja) 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
EA027071B1 (ru) 2009-04-27 2017-06-30 Новартис Аг АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
BR112012005225B8 (pt) 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
EP2496247B1 (en) 2009-11-03 2017-08-23 Acceleron Pharma, Inc. Methods for treating fatty liver disease
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
KR20220075438A (ko) 2011-10-17 2022-06-08 악셀레론 파마 인코포레이티드 비효율적 적혈구생성 치료를 위한 방법 및 조성물
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
US20140303068A1 (en) 2011-10-28 2014-10-09 Paranta Biosciences Limited Method of treating mucus hypersecretion
PE20142114A1 (es) 2011-12-19 2015-01-04 Amgen Inc Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
EP2830642B1 (en) 2012-03-30 2019-08-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2861620A2 (en) 2012-06-14 2015-04-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
EP2868667B1 (en) 2012-07-02 2019-01-30 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
AU2013334660B2 (en) 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
WO2014066486A2 (en) 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
ES3023054T3 (en) 2012-11-08 2025-05-29 Clearside Biomedical Inc Methods for the treatment of ocular disease in human subjects
CN103047581B (zh) 2012-12-04 2015-04-01 京东方科技集团股份有限公司 背光模组及具有该背光模组的显示装置
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
CA2932463A1 (en) 2013-12-16 2015-06-25 Paranta Biosciences Limited Method of diagnosis and treatment
HK1231513A1 (zh) 2014-01-14 2017-12-22 Santa Maria Biotherapeutics, Inc. 活化素抑制劑應答預測和用於治療的用途
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
US20160046690A1 (en) 2014-03-21 2016-02-18 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ, インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
EA201692568A1 (ru) 2014-06-13 2017-05-31 Санта Мария Биотерапевтикс, Инк. Составы с полипептидами-рецепторами и связанные с ними способы
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
IL252631B2 (en) 2014-12-03 2024-06-01 Celgene Corp ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
JOP20160092B1 (ar) 2015-05-13 2023-03-28 Celgene Corp علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CN108697793B (zh) 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
HUE067225T2 (hu) 2016-07-27 2024-10-28 Acceleron Pharma Inc Mielofibrózis kezelésére szolgáló készítmények

Also Published As

Publication number Publication date
KR20220156979A (ko) 2022-11-28
US10195249B2 (en) 2019-02-05
CN104936605A (zh) 2015-09-23
EP2914277A4 (en) 2016-05-25
CA2890217C (en) 2021-07-20
IL267066A (en) 2019-08-29
EP3964224A1 (en) 2022-03-09
CA2890217A1 (en) 2014-05-08
IL238443A0 (en) 2015-06-30
KR20210091358A (ko) 2021-07-21
AU2018236696A1 (en) 2018-10-18
AU2020213397A1 (en) 2020-08-27
RU2015120804A (ru) 2016-12-27
KR102279522B1 (ko) 2021-07-19
MX366336B (es) 2019-07-05
JP2020143164A (ja) 2020-09-10
AU2013337677A1 (en) 2015-05-21
MX389254B (es) 2025-03-20
EP3308796A1 (en) 2018-04-18
JP2016504275A (ja) 2016-02-12
BR112015009948B1 (pt) 2022-12-06
AU2013337677B2 (en) 2018-06-28
EP2914277B1 (en) 2017-09-13
RU2018145985A (ru) 2019-02-18
IL267066B (en) 2022-02-01
NZ707477A (en) 2019-09-27
RU2678117C2 (ru) 2019-01-23
US20230293634A1 (en) 2023-09-21
NZ747422A (en) 2021-04-30
EP2914277A1 (en) 2015-09-09
EP3308796B1 (en) 2021-07-14
ES2652437T3 (es) 2018-02-02
ZA201503135B (en) 2019-09-25
KR20150082423A (ko) 2015-07-15
ES2884095T3 (es) 2021-12-10
JP2018168176A (ja) 2018-11-01
JP2023011741A (ja) 2023-01-24
HK1214525A1 (en) 2016-07-29
US20190262423A1 (en) 2019-08-29
JP6714646B2 (ja) 2020-06-24
BR112015009948A8 (pt) 2021-10-19
CA3120678A1 (en) 2014-05-08
BR112015009948A2 (pt) 2017-07-11
HK1254086A1 (en) 2019-07-12
US20150283209A1 (en) 2015-10-08
WO2014071158A1 (en) 2014-05-08
MX2015005538A (es) 2016-02-05
MX2019008085A (es) 2019-09-09

Similar Documents

Publication Publication Date Title
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
ZA201404676B (en) Compositions and methods for treating metabolic disorders
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
IL225239A0 (en) Compounds for the treatment of acne and related diseases
IL237742A0 (en) Laquinimod and pridofidine for the treatment of neurodegenerative diseases
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL238223A0 (en) Methods and materials for the treatment of multiple sclerosis and diseases related to it
IL246246A0 (en) Converted piperidinyl-tetrahydroquinolines and their use as alpha-c2-adrenoreceptor antagonists
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
EP2916767A4 (en) DEVICES FOR TREATING TEETH NECKS
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
EP2919856A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
GB201203683D0 (en) Bone fixation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed